Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 2/20 | 1.00 |
| ▸ | GRM3 | Q14832 | 2/20 | 1.00 |
| ▸ | SLC1A1 | P43005 | 5/20 | 0.64 |
| ▸ | SLC1A2 | P43004 | 4/20 | 0.64 |
| ▸ | SLC1A3 | P43003 | 3/20 | 0.64 |
| ▸ | GRIK1 | P39086 | 5/20 | 0.57 |
| ▸ | GRIK2 | Q13002 | 4/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5664872 | 1.00 | GRM2 (1.00) | GRM2GRM3SLC1A1SLC1A2SLC1A3 | |
| SCHEMBL5282418 | 0.88 | GRM2 (0.79) | GRM2GRM3SLC1A1SLC1A2SLC1A3 | |
| SCHEMBL4257120 | 0.83 | GRM2 (1.00) | GRM2GRM3SLC1A1SLC1A2SLC1A3 | |
| SCHEMBL13917993 | 0.81 | GRM2 (0.68) | GRM2GRM3SLC1A1SLC1A2SLC1A3 | |
| SCHEMBL133913 | 0.78 | SLC1A1 (1.00) | GRM2GRM3SLC1A1SLC1A2SLC1A3 | |
| SCHEMBL2265548 | 0.78 | SLC1A1 (1.00) | GRM2GRM3SLC1A1SLC1A2SLC1A3 | |
| SCHEMBL130817 | 0.78 | SLC1A1 (1.00) | GRM2GRM3SLC1A1SLC1A2SLC1A3 | |
| SCHEMBL8377822 | 0.78 | SLC1A1 (1.00) | GRM2GRM3SLC1A1SLC1A2SLC1A3 | |
| SCHEMBL5286288 | 0.77 | GRM2 (0.62) | GRM2GRM3SLC1A1SLC1A2SLC1A3 | |
| SCHEMBL6448129 | 0.77 | GRM2 (0.62) | GRM2GRM3SLC1A1SLC1A2SLC1A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130210849-A1 | Methods for treating disorders associated with mGLU receptors including addiction and depression | MARKOU ATHINA (US) | 2013-08-15 | — | — | US | disclosed |
| US-8354447-B2 | mGLU receptors antagonists for treating disorders associated with mGLU receptors including addiction and depression | THE SCRIPPS RESEARCH INSTITUTE (US) | 2013-01-15 | — | — | US | disclosed |
| EP-1539149-B1 | COMBINATIONS OF METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS AND THEIR USE IN TREATING ADDICTIVE DISORDERS | NOVARTIS AG (CH) | 2012-01-04 | — | — | EP | disclosed |
| US-20060148835-A1 | Mglu receptors antagonists for treating disorders associated with mglu receptors including addiction and depression | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2006-07-06 | — | — | US | disclosed |
| EP-1539149-A2 | MGLU RECEPTORS ANTAGONISTS FOR TREATING DISORDERS ASSOCIATED WITH MGLU RECEPTORS INCLUDING ADDICTION AND DEPRESSION | Novartis AG (CH) | 2005-06-15 | — | — | EP | disclosed |
| WO-2004024150-A2 | MGLU RECEPTORS ANTAGONISTS FOR TREATING DISORDERS ASSOCIATED WITH MGLU RECEPTORS INCLUDING ADDICTION AND DEPRESSION | NOVARTIS AG (CH) | 2004-03-25 | — | — | WO | disclosed |